Neoplastic Process
Bayer and NextRNA Therapeutics Collaborate on $547 Million Deal to Develop Innovative Cancer Therapies Targeting Long Non-Coding RNAs
Bayer, NextRNA Therapeutics, lncRNA, small molecules, cancer, oncology, partnership, drug development
FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics
FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.
Cleveland Diagnostics Launches Second Annual Prostate Cancer Awareness Campaign
prostate cancer, IsoPSA test, Cleveland Diagnostics, awareness campaign, early detection
Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio
Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment
Regeneron Secures EU Approval for Lymphoma Treatment Ordspono Following FDA Rejection
Regeneron, EU approval, lymphoma, bispecific antibody, odronextamab, Ordspono, FDA rejection
FDA Rejects Regeneron’s Blood Cancer Bispecific, Delaying Competition with J&J and Pfizer
Regeneron, FDA rejection, blood cancer bispecific, linvoseltamab, multiple myeloma, J&J, Pfizer
PreciseDx Secures $20.7 Million in Series B Funding to Enhance AI-Driven Breast Cancer Risk Assessments
PreciseDx, AI-Powered Cancer Risk Assessments, Breast Cancer Diagnostics, Series B Funding, Precision Medicine
FDA Delays Approval of Regeneron’s Multiple Myeloma Drug Due to Manufacturing Issues
Regeneron, linvoseltamab, multiple myeloma, FDA rejection, manufacturing issues, bispecific antibody, cancer treatment
Merck & Co. Expands Oncology Pipeline with Kelun-Biotech ADCs
Merck & Co., Kelun-Biotech, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Oncology Pipeline
J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen